Upstate Active Clinical Trials

Study Title:

A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of this study is to evaluate how effective MEDI8897 is at preventing lung disease caused by RSV and to evaluate the safety and tolerability of MEDI8897 in healthy preterm infants compared with placebo (a saline solution that looks like the study drug but it does not contain active ingredient). The study will also measure drug levels of MEDI8897 in the blood, as well as looking at days missed from work and daycare.

Upstate Institutional Review Board (IRB) Number:

935423

Study/Protocol ID:

D5290C00003

Study Phase:

Phase II

Patient Age Group:

Children

Principal Investigator:

Joseph B Domachowske

Who can I contact for more information?

Name: Lori J Ferguson
Phone: 315-464-6331
Email: ferguslo@upstate.edu

Return to Previous Page || Search Again